Neogen (NEOG)

NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04

$11.83+1.63%

Close 2026-09-04 · 1-day change

Standing thesis

The standing, falsifiable read: what has to stay true, and what would break it.

Turnaround

Intact: The reason to own it still holds.

The bull case

Neogen aims for $857-$860 million revenue in fiscal 2026. It plans to finish Petrifilm manufacturing transition by November 2027. The company beat earnings in its last report. These show progress in fixing the business.

The bear case

Revenue fell 4.4% in the last quarter. The company still loses money. Management changes may slow progress.

What's priced in

The price is about 12% above our fair value near $8. Analysts expect about 3% revenue decline. We see some growth potential but risks remain.

What has to stay true

Sustain positive earnings per share growthImproving
Management ExecutionsupportingEPS >= $0.30 in FY26 · FY26 (consensus)
Breaks if: EPS falls below $0.25 in FY26
Complete Petrifilm manufacturing transition by November FY27Intact
Management ExecutionprimaryComplete by November FY27 · FY27-Q3 (qualitative)
Breaks if: Transition not complete by November FY27
Achieve fiscal 2026 revenue of at least $857 millionIntact
Revenue Growthprimary>= $857 million · FY26 (guidance)
Breaks if: Revenue falls below $845 million in FY26

Source: QuarterlyIQ research model· Written 2026-07-08· Health checked 2026-09-04· Version 1· Status: Intact· Reviewed when the evidence changes

This is not a price target or investment advice.

Current Outlook

Week of Sep 5, 2026

A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.

NEOG's long-term thesis remains intact amid strong recent performance and management priorities.

What kind of bet this is

This investment represents a durable compounder with a focus on long-term growth. The current thesis state is intact, supported by recent strong financial performance and management's commitment to key initiatives.

What's priced into Neogen (NEOG)

The market seems to have priced in a significant expectations gap, indicating that NEOG may be viewed as unjustified in its current premium compared to peers. The valuation reflects a medium level of confidence in its future performance.

What the fundamentals likely do

Management is on track with key priorities, including the transition of Petrifilm manufacturing and the planned divestiture of the Genomics business. However, there is an elevated risk due to industry peers missing earnings, which could impact NEOG's performance.

What Neogen (NEOG) hinges on

The thesis hinges on several factors, including management's ability to maintain guidance and the performance of sector bellwethers. Additionally, macroeconomic conditions, such as job growth and recession fears, could significantly impact NEOG's trajectory.

What changed in the latest read

What changed

The most important moves since the prior daily snapshot.

Short-term · Daily

No material changes since the prior snapshot.

Yes, our read has strengthened. The latest earnings beat supports revenue growth guidance for FY26. The company increased its revenue guidance to $857-$860 million. There are no new threats impacting the thesis.

as of 2026-09-04

See upcoming information that could change the risk

Review the evidence to watch, what would become a concern, and what would make it less concerning.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.